Astrazeneca reveals new oral, selective HPK1 inhibitor and prodrug to increase IO therapy response
March 21, 2024
Development and optimization of novel oral selective hematopoietic progenitor kinase 1 (HPK1) inhibitors for immuno-oncology (IO) treatment were reported by scientists from Astrazeneca plc in two presentations during the ACS meeting this week.